Sugi Predict

Sugi Predict / Targets / PDE7B

PDE7B

3',5'-cyclic-AMP phosphodiesterase 7B · Q9NP56 · PDE7B on Sugi Atlas →

19,066 patent compounds predicted against PDE7B, 13,906 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL100704 SCHEMBL100704 1.00 5/20
SCHEMBL100957 SCHEMBL100957 1.00 5/20
SCHEMBL101130 SCHEMBL101130 1.00 5/20
SCHEMBL100239 SCHEMBL100239 0.93 5/20
SCHEMBL100852 SCHEMBL100852 0.93 5/20
SCHEMBL100878 SCHEMBL100878 0.93 5/20
SCHEMBL99932 SCHEMBL99932 0.91 5/20
SCHEMBL100716 SCHEMBL100716 0.91 5/20
SCHEMBL100171 SCHEMBL100171 0.90 5/20
SCHEMBL100224 SCHEMBL100224 0.89 5/20
SCHEMBL99882 SCHEMBL99882 0.88 5/20
SCHEMBL99921 SCHEMBL99921 0.88 5/20
SCHEMBL100723 SCHEMBL100723 0.88 5/20
SCHEMBL100771 SCHEMBL100771 0.88 5/20
SCHEMBL100095 SCHEMBL100095 0.87 5/20
SCHEMBL100102 SCHEMBL100102 0.87 5/20
SCHEMBL100222 SCHEMBL100222 0.87 5/20
SCHEMBL100844 SCHEMBL100844 0.87 5/20
SCHEMBL100702 SCHEMBL100702 0.87 5/20
SCHEMBL100710 SCHEMBL100710 0.87 5/20

Clinical trials — most relevant to PDE7B by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Bosentan in Treatment of Pulmonary Arterial Hypertension PHASE4COMPLETED
Diabetic Artery Obstruction: is it Possible to Reduce Ischemic Events With Cilostazol? PHASE4COMPLETED
REmodelling in Diabetic CardiOmapathy: Gender Response to PDE5i InhibiTOrs PHASE4COMPLETED
Safety And Efficacy Of L-Arginine Monotherapy Versus Tadalafil Monotherapy Versus Their Combination In Men With Erectile Dysfunction; A Prospective Randomized Study PHASE4COMPLETED
Cardiovascular Effects of Chronic Sildenafil in Men With Type 2 Diabetes PHASE4COMPLETED
Use of Sildenafil Citrate in Management of Mild Pre-eclampsia PHASE2/PHASE3UNKNOWN
Chronic Sildenafil Treatment in Heart Failure PHASE3COMPLETED
The Efficacy and Safety of Vardenafil in the Treatment of Pulmonary Arterial Hypertension PHASE3COMPLETED
Genetic Factors of Erectile Dysfunction Degree and Response to Tadalafil Treatment in Patients With Diabetes PHASE3RECRUITING
Cilostazol With Nimodipine to Improve Outcome After Aneurysmal Subarachnoid Hemorrhage PHASE3NOT_YET_RECRUITING
Pentoxifylline as an Adjunctive in Treatment of Negative Symptoms in Chronic Schizophrenia PHASE1/PHASE2COMPLETED
The Phosphodiesterase 4 Inhibitor Roflumilast as an Adjunct to Antidepressants in Major Depressive Disorder Patients PHASE1/PHASE2WITHDRAWN
Theophylline Treatment for Pseudohypoparathyroidism - Children 2-12 Years Old PHASE2ACTIVE_NOT_RECRUITING
Title: Evaluation of a Novel PET Radioligand for Phosphodiesterase-4D (PDE4D) PHASE1/PHASE2COMPLETED
The Controlled Trial of Apremilast for Rheumatoid Arthritis Treatment (CARAT) PHASE2COMPLETED
Tadalafil for Pulmonary Hypertension Due to Chronic Lung Disease PHASE2COMPLETED
Safety Study of Sildenafil in Treatment of Cerebral Aneurysm Vasospasm PHASE2WITHDRAWN
PDE5 Inhibition for Obesity-Related Cardiometabolic Dysfunction PHASE2COMPLETED
Cilostazol and Its Effects on Resumption of Meiosis in the Human Ovary PHASE2COMPLETED
Safety, Efficacy and Pharmacokinetic Between Capecitabine and Exisulind in Metastatic Breast Cancer Patients PHASE1/PHASE2COMPLETED
Safety Study of the Effect of Scelectium Tortuosum (as Zembrin®)in Aged Normals PHASE1COMPLETED
PET Whole Body Biodistribution and Test Retest Bain Imaging Studies Using a Phosphodiesterase 4 Inhibitor (R)-[11C]Rolipram PHASE1COMPLETED
Vitamin D Versus Sildenafil Citrate in Fetal Growth Restriction PHASE1COMPLETED
[18F]PF-06445974 to Image PDE4B in Major Depressive Disorder Using PET PHASE1RECRUITING
Evaluation the Topical Apremilast Nanoformulation in Treatment of Localized Plaque Psoriasis nanNOT_YET_RECRUITING
The Phosphodiesterase-3 Inhibitor Cilostazol as an Adjunctive to Antidepressants in Patients With Major Depressive Disorder. nanCOMPLETED
Clinical Characterization on PDE6A-related Retinitis Pigmentosa in Preparation to a Gene Therapy Trial nanCOMPLETED
Silodosin, Tadalafil Alone vs. Silodosin Plus Tadalafil as MET for Lower Ureteric Stones nanCOMPLETED
Intravenous Terbutaline in Severe Status Asthmaticus nanUNKNOWN
Platelet and Tissue cAMP: Novel Biomarkers of Milrinone Efficacy in Children nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a PDE7B binder may also engage these)

ProteinNameSimilarity
Q9QXQ1 — 1.000 Q9QXQ1 →
PDE7A High affinity 3',5'-cyclic-AMP phosphodiesterase 7A 0.988 landscape →
O08593 — 0.986 O08593 →
P70453 — 0.985 P70453 →
Q01066 — 0.956 Q01066 →
A4IJ06 — 0.955 A4IJ06 →
Q6AYG3 — 0.953 Q6AYG3 →
Q6NTL4 — 0.953 Q6NTL4 →
Q6ZT62 — 0.953 Q6ZT62 →
Q01065 — 0.952 Q01065 →
Q64395 — 0.952 Q64395 →
Q8BY35 — 0.952 Q8BY35 →
PRUNE1 Exopolyphosphatase PRUNE1 0.952 landscape →
Q69ZK0 — 0.952 Q69ZK0 →
Q01061 — 0.951 Q01061 →
PDE10A cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A 0.951 landscape →
Q5E9Y6 — 0.951 Q5E9Y6 →
O88954 — 0.950 O88954 →
Q9UPU7 — 0.950 Q9UPU7 →
Q5SV80 — 0.950 Q5SV80 →
Q9R144 — 0.949 Q9R144 →
Q96MI9 — 0.949 Q96MI9 →
Q8N5V2 — 0.949 Q8N5V2 →
PDE1B Dual specificity calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1B 0.949 landscape →
Q5XGZ2 — 0.949 Q5XGZ2 →
Q5FVI9 — 0.949 Q5FVI9 →
Q9Z1S3 — 0.949 Q9Z1S3 →
Q3U0J8 — 0.949 Q3U0J8 →
Q13368 — 0.948 Q13368 →
Q9HA65 — 0.948 Q9HA65 →